Histone deacetylase inhibitors promote breast cancer metastasis …
2023年1月6日 · In this study, we declare that pan-HDAC inhibitors targeting NEDD9-FAK pathway exacerbate breast cancer metastasis in preclinical models, which may severely impede their clinical success.
HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
Additionally, this innovative HDAC1 inhibitor demonstrated potent in vivo antitumor efficacy in human MDA-MB-231 breast cancer xenograft model. Moreover, compound 8 had the ability to impede microtubule assembly and downregulate tubulin …
HDAC inhibitor suppresses proliferation and invasion of breast cancer ...
HDAC inhibitors and the ectopic expression of miR-200c as tumor suppressors inhibited the proliferation, invasion, and migration of breast cancer cells by downregulating CRKL. These results indicate that the anticancer mechanism of HDAC inhibitor was realized partially by regulating miR-200c via CRKL targeting.
Recent advancement of HDAC inhibitors against breast cancer
2023年6月9日 · Recent studies highlight the great potential impact of HDAC inhibitors (HDACis) in suppressing TNBC, even though clinical trials including a single HDACis demonstrated unsatisfactory outcomes against TNBC. New compounds created to achieve isoform selectivity and/or a polypharmacological HDAC strategy have also produced interesting results.
Recent advancement of HDAC inhibitors against breast cancer
2023年6月9日 · Recent studies highlight the great potential impact of HDAC inhibitors (HDACis) in suppressing TNBC, even though clinical trials including a single HDACis demonstrated unsatisfactory outcomes against TNBC. New compounds created to achieve isoform selectivity and/or a polypharmacological HDAC strateg …
Tackling triple negative breast cancer with HDAC inhibitors: 6 is …
2024年12月5日 · In this review we showcase the latest evidence supporting the involvement of histone deacetylase 6 (HDAC6) in cancer pathways strictly related to TNBC subtype, also tracking the latest advancements in the identification of novel HDAC6 inhibitors which showed efficacy in TNBC models, offering insights into the potential of targeting this key epig...
HDAC6 as a Prognostic Factor and Druggable Target in HER2 …
The mechanisms of action of HDAC inhibitors and the biological effects of HDAC inhibition are far from being completely understood ... Hu Z., Wei F., Su Y., Wang Y., Shen Y., Fang Y., Ding J., Chen Y. Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression. Signal Transduct. Target. Ther. 2023;8:11. doi: 10 ...
Clinical trial landscape for histone deacetylation inhibitors in breast ...
2024年11月28日 · Immunotherapy has revolutionized the landscape of tumor treatment and is getting widespread attention in treating triple negative breast cancer (TNBC). To date, the number of trials testing HDAC inhibitors plus immunotherapy has remained relatively low compared to other combinations like hormone therapy or chemotherapy.
Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy ...
2023年9月3日 · Novel pyrazino -hydrazide-based HDAC3 inhibitors were designed and synthesized. Lead compound 4i exhibited potent HDAC3 inhibition (IC 50 = 14 nM) with at least 121-fold selectivity. It demonstrated strong cytotoxicity against triple-negative breast cancer cells (IC 50: 0.55 μM for 4T1, 0.74 μM for MDA-MB-231) with least normal cell toxicity.
Overcoming doxorubicin resistance in triple-negative breast cancer ...
2024年3月1日 · Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDAC) inhibitor that promotes apoptosis in TNBC preclinical models. The purpose of this study was to investigate the combination of bocodepsin and doxorubicin in preclinical TNBC models and evaluate the impact on terminal cell fate, including apoptosis and senescence.
- 某些结果已被删除